Tags

Type your tag names separated by a space and hit enter

Effects of clarithromycin in patients with active rheumatoid arthritis.
Curr Med Res Opin. 2007 Mar; 23(3):515-22.CM

Abstract

OBJECTIVE

To evaluate the clinical efficacy, safety, and tolerability of clarithromycin in patients with rheumatoid arthritis.

RESEARCH DESIGN AND METHODS

This was a 6-month, monocenter, randomized, double-blind, placebo-controlled study. A total of 81 patients with early rheumatoid arthritis were treated with either once-daily oral clarithromycin (500 mg) or daily oral placebo for 6 months.

MAIN OUTCOME MEASURES

The primary efficacy variable was the percentage of patients who had a 20% improvement according to American College of Rheumatology (ACR) criteria (an ACR 20 response) at 6-months. Secondary outcome measures were 50% improvement and 70% improvement according to ACR criteria (an ACR 50 response and an ACR 70 response, respectively).

RESULTS

A significantly greater percentage of patients treated with 500 mg clarithromycin met the ACR 20 response at 6 months compared with patients who received placebo (59 vs. 33%; p < 0.001). Greater percentages of patients treated with 500 mg clarithromycin also achieved ACR 50 responses (34 vs. 10%; p < 0.001) and ACR 70 responses (20 vs. 3%; p = 0.003) compared with patients who received placebo, respectively. Clarithromycin was well tolerated. There were no dose-limiting toxic effects.

CONCLUSIONS

In patients with early active rheumatoid arthritis, treatment with clarithromycin significantly improved the signs and symptoms of rheumatoid arthritis. Clarithromycin has been shown to be effective against rheumatoid arthritis.

Authors+Show Affiliations

Division of Rheumatology, Nazilli State Hospital, Nazilli, Turkey. prevotella@mynet.com <prevotella@mynet.com>

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17355733

Citation

Ogrendik, Mesut. "Effects of Clarithromycin in Patients With Active Rheumatoid Arthritis." Current Medical Research and Opinion, vol. 23, no. 3, 2007, pp. 515-22.
Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin. 2007;23(3):515-22.
Ogrendik, M. (2007). Effects of clarithromycin in patients with active rheumatoid arthritis. Current Medical Research and Opinion, 23(3), 515-22.
Ogrendik M. Effects of Clarithromycin in Patients With Active Rheumatoid Arthritis. Curr Med Res Opin. 2007;23(3):515-22. PubMed PMID: 17355733.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of clarithromycin in patients with active rheumatoid arthritis. A1 - Ogrendik,Mesut, PY - 2007/3/16/pubmed PY - 2007/3/31/medline PY - 2007/3/16/entrez SP - 515 EP - 22 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 23 IS - 3 N2 - OBJECTIVE: To evaluate the clinical efficacy, safety, and tolerability of clarithromycin in patients with rheumatoid arthritis. RESEARCH DESIGN AND METHODS: This was a 6-month, monocenter, randomized, double-blind, placebo-controlled study. A total of 81 patients with early rheumatoid arthritis were treated with either once-daily oral clarithromycin (500 mg) or daily oral placebo for 6 months. MAIN OUTCOME MEASURES: The primary efficacy variable was the percentage of patients who had a 20% improvement according to American College of Rheumatology (ACR) criteria (an ACR 20 response) at 6-months. Secondary outcome measures were 50% improvement and 70% improvement according to ACR criteria (an ACR 50 response and an ACR 70 response, respectively). RESULTS: A significantly greater percentage of patients treated with 500 mg clarithromycin met the ACR 20 response at 6 months compared with patients who received placebo (59 vs. 33%; p < 0.001). Greater percentages of patients treated with 500 mg clarithromycin also achieved ACR 50 responses (34 vs. 10%; p < 0.001) and ACR 70 responses (20 vs. 3%; p = 0.003) compared with patients who received placebo, respectively. Clarithromycin was well tolerated. There were no dose-limiting toxic effects. CONCLUSIONS: In patients with early active rheumatoid arthritis, treatment with clarithromycin significantly improved the signs and symptoms of rheumatoid arthritis. Clarithromycin has been shown to be effective against rheumatoid arthritis. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/17355733/Effects_of_clarithromycin_in_patients_with_active_rheumatoid_arthritis_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079906X167642 DB - PRIME DP - Unbound Medicine ER -